
First planet of its kind with ‘gargantuan' comet-like tail discovered
The Mercury -sized planet, dubbed BD+05 4868 Ab, is 140 light years away from Earth and located in the constellation of Pegasus, according to a new study published in The Astrophysical Journal Letters.
It is so close to its star that it is covered in magma and is boiling off into space, say researchers from the Massachusetts Institute of Technology (MIT).
While observing a section of space using Nasa's exoplanet surveying satellite, scientists found a peculiar periodic dip in starlight that tipped them off about the presence of a rocky planet with a long, comet-like tail of debris.
'The extent of the tail is gargantuan, stretching up to 9 million kilometres long, or roughly half of the planet's entire orbit,' said Marc Hon, one of the authors of the study from MIT.
Inspecting the planet further, they found that it is disintegrating at a dramatic rate, shedding a Mount Everest -equivalent of debris each time it orbits its star about every 30 hours.
Given the planet's mass, researchers suspect it may completely disintegrate in about a million years.
'We got lucky with catching it exactly when it's going away ... It's like on its last breath,' said Avi Shporer, another author of the study.
Typically, astronomers identify planets orbiting stars by looking for a brief dip in a light curve that repeats regularly.
This is the signal one might expect from a star as it passes in front of, and temporarily blocks, the light from its star.
However, when looking at the host star of BD+05 4868 A, they found that its brightness dip took much longer to return to normal.
This suggested that a long trailing structure was still blocking starlight.
Researchers found it even more intriguing that the depth of the light dip changed with each orbit, meaning the object passing in front of the star wasn't always the same size or shape.
'The shape of the transit is typical of a comet with a long tail,' said Marc Hon, another author of the study.
'Except that it's unlikely that this tail contains volatile gases and ice as expected from a real comet – these would not survive long at such proximity to the host star,' Dr Hon explained.
Scientists then came to the conclusion that what they were seeing was actually mineral grains evaporating from the surface of a planet that tend to linger long enough to form a distinctive tail.
'This is a very tiny object, with very weak gravity, so it easily loses a lot of mass, which then further weakens its gravity, so it loses even more mass. It's a runaway process, and it's only getting worse and worse for the planet,' Dr Shporer said.
While planets with such comet-like tails have been spotted before, these past observations were at least a decade ago.
Among the three other disintegrating planets spotted outside our solar system, BD+05 4868 Ab has the longest tail to date, researchers say.
'That implies that its evaporation is the most catastrophic, and it will disappear much faster than the other planets,' scientists concluded.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


STV News
2 days ago
- STV News
AI designs drugs to combat gonorrhoea and MRSA
Artificial intelligence has helped researchers to design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA. A team at Massachusetts Institute of Technology used AI algorithms to design more than 36 million possible compounds and screen them for antimicrobial properties. The top candidates appeared to be different from any existing antibiotics, and researchers say they work through mechanisms that disrupt bacterial cell membranes. The use of AI allowed scientists to generate and test compounds that had never been seen before. Senior author of the study Professor James Collins said the team is 'excited' about the new possibilities opened up by this project. 'Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,' he said. The team used generative AI algorithms to design molecules based on a specific chemical fragment that showed antimicrobial activity, but they then also let the algorithms freely generate molecules that didn't require that specific fragment. Bacterial resistance to many antibiotics is also increasing – nearly five million deaths each year are caused by drug-resistant bacterial infections. 'We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way,' lead author Aarti Krishnan said. 'By venturing into underexplored areas of chemical space, our goal was to uncover novel mechanisms of action.' It is rare that new antibiotics are discovered and later approved by health authorities. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country


The Independent
2 days ago
- The Independent
How researchers developed drugs to fight antimicrobial resistance
Researchers at the Massachusetts Institute of Technology (MIT) have utilised artificial intelligence to develop two new antibiotics. These drugs, named NG1 and DN1, have shown effectiveness against drug-resistant strains of gonorrhoea and MRSA in lab and animal tests. The new compounds attack bacterial membranes in novel ways, offering hope that bacteria will find it harder to develop resistance compared to existing medicines. This breakthrough addresses the growing global public health crisis of antimicrobial resistance, which is responsible for over one million deaths annually. The antibiotics are currently in early development and require extensive testing, including clinical trials, to prove their safety and efficacy in humans.


The Independent
3 days ago
- The Independent
Scientists use AI to create new antibiotics that can kill deadly drug-resistant superbugs
Researchers have developed antibiotics that can potentially kill drug-resistant gonorrhoea and MRSA with the help of artificial intelligence. The team at the Massachusetts Institute of Technology (MIT) used generative AI algorithms to design more than 36 million molecular compounds, identifying two new drugs that were then tested in lab settings and in mice. According to their study, published in Cell on Thursday, the AI scanned through a list of potential molecules and predicted which ones could work as antibiotics, while also avoiding structures that could be harmful to humans or too similar to existing drugs. Both new antibiotics were able to kill strains of bacteria that are becoming increasingly difficult to treat with existing antibiotics. One of the new drugs, called NG1, was designed to specifically target gonorrhoea, a sexually transmitted infection that has been rapidly developing resistance to antibiotics. The World Health Organisation has warned that gonorrhoea is becoming untreatable in some cases due to antibiotic resistance. New data from the UK Health Security Agency (UKHSA) reveals a concerning increase in resistant cases. Between January 2024 and March 2025, 17 cases of ceftriaxone-resistant gonorrhoea were reported, 13 in 2024 and four in the first three months of 2025. The second drug, named DN1, was effective against methicillin-resistant staphylococcus aureus (MRSA), a type of staph infection that no longer responds to many commonly used antibiotics. MRSA often begins as a painful, pus‑filled skin boil and can spread to cause serious, hard‑to‑treat infections in the bloodstream, lungs or bones, especially in people with weakened immune systems. After tests, it was found that NG1 and DN1 stood out for their ability to kill dangerous bacteria in both test tubes and mice. In animal studies, the drugs were able to successfully treat skin infections caused by MRSA and clear gonorrhoea infections. The team also hopes to use their AI platform to design new drugs for other superbugs in the future, including those that cause tuberculosis and hospital-acquired infections like Pseudomonas aeruginosa. 'We're excited about the new possibilities that this project opens up for antibiotics development,' said James Collins, senior author of the study and Termeer Professor of Medical Engineering and Science in MIT's Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering. 'Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible.' What makes this discovery significant is that both drugs work in new ways. Many antibiotics rely on similar mechanisms to kill bacteria, which has allowed some bacteria to evolve resistance over time. These new compounds appear to attack bacterial membranes in ways not used by current medicines, giving scientists hope that they could be harder for bacteria to resist. 'We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way,' said Aarti Krishnan, lead author and MIT postdoc. Although the findings are promising, the researchers have stressed that these new antibiotics are still in early development. They must go through years of testing to prove they are safe and effective in humans. The next steps include refining the chemical structure of the drugs, testing for potential side effects, and eventually conducting clinical trials. Antimicrobial resistance, or when bacteria evolve to resist the drugs used to kill them, is a growing public health crisis. It is estimated to be responsible for more than one million deaths globally each year, with experts warning that without urgent action, even minor infections could once again become deadly. In the UK, there were 66,730 serious antibiotic-resistant infections recorded in 2023 alone, according to a report by The Times.